BioGaia ABBGLAF 100 PE Ratio (TTM) is 34.96 as of Jun. 28, 2026, which is 2% above its 10-year median of 34.17. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 634 Drug Manufacturers companies, BioGaia AB ranks worse than 70.03% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-28), BioGaia AB's share price is
$12.20.
BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35. Therefore, BioGaia AB's PE Ratio (TTM) for today is 34.96.
Warning Sign:
BioGaia AB stock PE Ratio (=36.22) is close to 3-year high of 39.91.
The historical rank and industry rank for BioGaia AB's PE Ratio (TTM) or its related term are showing as below:
BGLAF'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 21.01 Med: 34.17 Max: 61.38
Current: 36.22
During the past 13 years, the highest PE Ratio (TTM) of BioGaia AB was 61.38. The lowest was 21.01. And the median was 34.17.
BGLAF's PE Ratio (TTM) is ranked worse than 70.03% of 634
companies
in the Drug Manufacturers industry
Industry Median: 20.405
vs BGLAF: 36.22
As of today (2026-06-28), BioGaia AB's share price is $12.20.
BioGaia AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35. Therefore, BioGaia AB's PE Ratio without NRI for today is 34.96.
During the past 13 years, BioGaia AB's highestPE Ratio without NRI was 61.38. The lowest was 22.33. And the median was 34.86.
BioGaia AB's EPS without NRI for the
three
months ended in Mar. 2026 was $0.08.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35.
During the past 12 months, BioGaia AB's average EPS without NRIGrowth Rate was 7.20% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 3.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 13.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 7.90% per year.
During the past 13 years, BioGaia AB's highest 3-Year average EPS without NRI Growth Rate was 135.50% per year. The lowest was -40.50% per year. And the median was 13.95% per year.
BioGaia AB's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.08.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35.
BioGaia AB (OTCPK:BGLAF) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
BioGaia AB PE Ratio (TTM) Related Terms
BioGaia AB PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for BioGaia AB's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where BioGaia AB's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
BioGaia AB's PE Ratio (TTM) for today is calculated as
BioGaia AB's Share Price of today is $12.20.
BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
BioGaia AB (BGLAF) has a PE Ratio (TTM) of 34.96 as of Jun. 28, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on BioGaia AB and its competitors. This is near median its historical median of 34.17. Over the past decade, BioGaia AB's PE Ratio (TTM) has ranged from 21.01 to 61.38. According to the industry distribution chart, BioGaia AB ranks #444 out of 634 companies in the Drug Manufacturers industry, placing it in the top 70%.
Is BioGaia AB's PE Ratio (TTM) too high?
BioGaia AB's current PE Ratio (TTM) of 34.96 is near median its 10-year median of 34.17. Over the past 10 years, this metric has ranged from a low of 21.01 to a high of 61.38. The Drug Manufacturers industry median PE Ratio (TTM) is 20.41. BioGaia AB's value of 34.96 is 71.3% above this industry median. Based on the distribution chart, BioGaia AB ranks #444 out of 634 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's PE Ratio (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #444 out of 634 companies for PE Ratio (TTM). This places BioGaia AB in the lower half of its industry. The industry median PE Ratio (TTM) is 20.41. BioGaia AB's value of 34.96 is 71.3% above this benchmark. Historically, BioGaia AB's own PE Ratio (TTM) has ranged from 21.01 to 61.38 over the past decade. While the company's 10-year median is 34.17 vs. the industry median of 20.41, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 20.41, based on 634 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current PE Ratio (TTM) of 34.96 is 71.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 20.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current PE Ratio (TTM) is 34.96, which is near median its own 10-year median of 34.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current PE Ratio (TTM) of 34.96. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current PE Ratio (TTM) is 34.96, which is near median its 10-year median of 34.17 and 71.3% above the Drug Manufacturers industry median of 20.41. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current PE Ratio (TTM) is 34.96 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
PE Ratio (TTM): 34.96 (near median its 10-year median of 34.17)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 71.3% above the Drug Manufacturers median (#444 of 634)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
